Volume 67, Pages S3-S9 (January 2005)

Slides:

Advertisements

Similar presentations

Renal Stress Testing in the Assessment of Kidney Disease Lakhmir S. Chawla, Claudio Ronco Kidney International Reports Volume 1, Issue 1, Pages (May.

Advertisements

Chapter 1: Definition and classification of CKD Kidney International Supplements Volume 3, Issue 1, Pages (January 2013) DOI: /kisup

Improved patient/technique survival and peritonitis rates in patients treated with automated peritoneal dialysis when compared to continuous ambulatory.

Pathophysiology of renal fluid retention

V.M. Campese, N. Mitra, D. Sandee Kidney International

Volume 70, Issue 10, Pages (November 2006)

Combination therapy with ACE inhibitors and angiotensin II receptor blockers in chronic renal disease: New therapeutic world beyond blood pressure reduction

Viper venom for diabetic nephropathy

Volume 66, Issue 5, Pages (November 2004)

Membranous nephropathy: When and how to treat

Viper venom for diabetic nephropathy

Progression of renal failure and hypertensive nephrosclerosis

Volume 77, Issue 1, Pages 6-8 (January 2010)

Pathophysiology of renal fluid retention

Francesco Paolo Schena Kidney International

Audit-based education: a potentially effective program for improving guideline achievement in CKD patients Moniek C.M. de Goeij, Joris I. Rotmans Kidney.

The intrarenal renin-angiotensin system in hypertension

Volume 59, Issue 4, Pages (April 2001)

V.M. Campese, N. Mitra, D. Sandee Kidney International

Effects of antihypertensive therapy on intrarenal angiotensin and bradykinin levels in experimental renal insufficiency Fiona E. Mackie, Timothy W. Meyer,

Volume 55, Issue 1, Pages (January 1999)

Comorbidity and confounding in end-stage renal disease

Volume 63, Issue 2, Pages (February 2003)

Volume 70, Issue 11, Pages (December 2006)

Renal risk scores: Progress and prospects

The epidemiology of chronic kidney disease

Impaired response of the denervated kidney to endothelin receptor blockade in normotensive and spontaneously hypertensive rats Radoslav Girchev, Angela.

Up-regulation of kidney NAD(P)H oxidase and calcineurin in SHR: Reversal by lifelong antioxidant supplementation Chang-de Zhan, Ram K. Sindhu, Nosratola.

Saulo Klahr, Jeremiah J. Morrissey Kidney International

Volume 70, Issue 12, Pages (December 2006)

Volume 61, Issue 1, Pages S106-S109 (January 2002)

Improved patient/technique survival and peritonitis rates in patients treated with automated peritoneal dialysis when compared to continuous ambulatory.

Volume 70, Issue 7, Pages (October 2006)

Volume 67, Pages S63-S68 (January 2005)

Fructose intake as a risk factor for kidney stone disease

Special deLIVERy: podocyte injury promotes renal angiotensin II generation from liver- derived angiotensinogen David I. Ortiz-Melo, Robert F. Spurney

Angiotensin-(1–7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells Z. Su, J. Zimpelmann, K.D. Burns Kidney.

Volume 68, Issue 2, Pages (August 2005)

Impact of gender on the renal response to angiotensin II

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Angiotensin II production and distribution in the kidney – II

Volume 87, Issue 1, Pages (January 2015)

William J. Welch, Christopher S. Wilcox Kidney International

Efferent arteriole tubuloglomerular feedback in the renal nephron

Volume 67, Pages S52-S54 (January 2005)

Counteracting progression of renal disease: A look into the future

Unilateral renal cystic disease

Volume 57, Issue 2, Pages (October 2000)

Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors Barry M. Brenner, Joann Zagrobelny

Volume 63, Issue 1, Pages (January 2003)

Carmine Zoccali, Francesca Mallamaci Kidney International

Peritoneal dialysis in Mexico

Clinical benefits of slowing the progression of renal failure

Organ transplantation goes to the movies

Volume 55, Pages S3-S16 (June 1999)

Volume 68, Issue 5, Pages (November 2005)

Volume 80, Issue 10, Pages (November 2011)

Charles A. Herzog Kidney International

Is complement a target for therapy in renal disease?

Volume 54, Pages S207-S210 (September 1998)

Does an apple a day put hypertension in play?

Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: Pathophysiology and indications

Volume 66, Issue 4, Pages (October 2004)

T cells and T-cell receptors in acute renal failure

Renal vascular disease in the elderly

Volume 57, Issue 2, Pages (October 2000)

Volume 62, Pages S2-S7 (December 2002)

Volume 74, Pages S4-S9 (December 2008)

Epidemiologic data of renal diseases from a single unit in China: Analysis based on 13,519 renal biopsies Lei-Shi Li, Zhi-Hong Liu Kidney International

Presentation transcript:

Volume 67, Pages S3-S9 (January 2005) AT-1 receptor antagonism modifies the mediation of endothelin-1, thromboxane A2, and catecholamines in the renal constrictor response to angiotensin II E.V.A. Cediel, Natalia de las Heras, David Sanz-Rosa, Olga Velasco, Victoria Cachofeiro, Vicente Lahera Kidney International Volume 67, Pages S3-S9 (January 2005) DOI: 10.1111/j.1523-1755.2005.09302.x Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 1 Concentration-dependent increases in renal perfusion pressure (RPP) produced by angiotensin II (Ang II) in isolated kidneys from WKY and SHR, untreated and treated with irbesartan. Kidney International 2005 67, S3-S9DOI: (10.1111/j.1523-1755.2005.09302.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 2 Concentration-dependent reductions produced by the alfa-1 receptor antagonist prazosin on the increase in perfusion pressure produced by angiotensin II (10−5 mol/L) in isolated kidneys from WKY and SHR, untreated and treated with irbesartan. Kidney International 2005 67, S3-S9DOI: (10.1111/j.1523-1755.2005.09302.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 3 Concentration-dependent reductions produced by the TXA2/PGH2 receptor antagonist ifetroban on the increase in perfusion pressure produced by angiotensin II (10−5 mol/L) in isolated kidneys from WKY and SHR, untreated and treated with irbesartan. Kidney International 2005 67, S3-S9DOI: (10.1111/j.1523-1755.2005.09302.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 4 Concentration-dependent reductions produced by the ETA/ETB receptor antagonist PD145065 on the increase in perfusion pressure produced by angiotensin II (10−5 mol/L) in isolated kidneys from WKY and SHR, untreated and treated with irbesartan. Kidney International 2005 67, S3-S9DOI: (10.1111/j.1523-1755.2005.09302.x) Copyright © 2005 International Society of Nephrology Terms and Conditions